

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

☒ Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person * <u>Derynck Mika K</u> (Last) (First) (Middle) <u>C/O ENLIVEN THERAPEUTICS, INC.</u> <u>205 PARK ROAD</u> (Street) <u>BURLINGAME CA</u> <u>94010</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Enliven Therapeutics, Inc.</u> [<u>ELVN</u>] Foreign Trading Symbol 3. Date of Earliest Transaction (Month/Day/Year) <u>08/04/2026</u> 4. If Amendment, Date of Original Filed (Month/Day/Year)	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) ☒ Director 10% Owner Officer (give title below) Other (specify below) 6. Individual or Joint/Group Filing (Check Applicable Line) ☒ Form filed by One Reporting Person Form filed by More than One Reporting Person
---	---	---

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	08/04/2026		M ⁽¹⁾		87,373	A	\$2.48	87,373	D	
Common Stock	08/04/2026		M ⁽¹⁾		27,567	A	\$25.28	114,940	D	
Common Stock	08/04/2026		M ⁽¹⁾		23,364	A	\$14.85	138,304	D	
Common Stock	08/04/2026		M ⁽¹⁾		20,491	A	\$22.47	158,795	D	
Common Stock	08/04/2026		S ⁽¹⁾		158,795	D	\$60.2134 ⁽²⁾	0	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$2.48	08/04/2026		M ⁽¹⁾		87,373	(3)	08/01/2031	Common Stock	87,373	\$0	0	D	
Stock Option (right to buy)	\$25.28	08/04/2026		M ⁽¹⁾		27,567	(3)	02/23/2033	Common Stock	27,567	\$0	0	D	
Stock Option (right to buy)	\$14.85	08/04/2026		M ⁽¹⁾		23,364	(3)	02/13/2034	Common Stock	23,364	\$0	0	D	
Stock Option (right to buy)	\$22.47	08/04/2026		M ⁽¹⁾		20,491	(3)	02/06/2035	Common Stock	20,491	\$0	0	D	

Explanation of Responses:

1. The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2025.
2. This transaction was executed in multiple trades at prices ranging from \$60.00 to \$60.58. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
3. All of the shares subject to this option are fully vested and exercisable as of the date hereof.

/s/ Ben Hohl, by power of attorney
** Signature of Reporting Person

08/06/2026
Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

